BR112018016300A2 - fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenoso - Google Patents

fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenoso

Info

Publication number
BR112018016300A2
BR112018016300A2 BR112018016300A BR112018016300A BR112018016300A2 BR 112018016300 A2 BR112018016300 A2 BR 112018016300A2 BR 112018016300 A BR112018016300 A BR 112018016300A BR 112018016300 A BR112018016300 A BR 112018016300A BR 112018016300 A2 BR112018016300 A2 BR 112018016300A2
Authority
BR
Brazil
Prior art keywords
diabetes
vitiligo
gout
acne
prevention
Prior art date
Application number
BR112018016300A
Other languages
English (en)
Inventor
Beer Hans-Dietmar
E French Lars
Garstkiewicz Martha
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of BR112018016300A2 publication Critical patent/BR112018016300A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

trata-se de um composto especificado pela fórmula (i), em particular, dimetilfumarato (éster dimetílico de ácido trans-1,2-etilenodicarboxílico) fornecido para uso na prevenção ou na terapia de gota, acne, pioderma gangrenoso, vitiligo, doença cardiovascular, síndrome metabólica, diabetes e/ou complicações de diabetes. também são fornecidos uma forma de dosagem que compreende o dito composto e um método de tratamento que compreender administrar o dito composto a um paciente em necessidade do mesmo.
BR112018016300A 2016-02-12 2017-02-10 fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenoso BR112018016300A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16155554 2016-02-12
EP16175524 2016-06-21
EP16177215 2016-06-30
EP16202534 2016-12-06
PCT/EP2017/053029 WO2017137576A1 (en) 2016-02-12 2017-02-10 Dimethyl fumarate (dmf) for prevention or treatment of gout, acne, diabetes, vitiligo and/or pyoderma gangrenosum

Publications (1)

Publication Number Publication Date
BR112018016300A2 true BR112018016300A2 (pt) 2018-12-26

Family

ID=58018104

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016300A BR112018016300A2 (pt) 2016-02-12 2017-02-10 fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenoso

Country Status (6)

Country Link
US (1) US20190029987A1 (pt)
EP (1) EP3413884A1 (pt)
JP (1) JP2019510743A (pt)
AU (1) AU2017216861A1 (pt)
BR (1) BR112018016300A2 (pt)
WO (1) WO2017137576A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3956342A4 (en) * 2019-02-15 2023-05-24 Triterpenoid Therapeutics, Inc. METHODS AND COMPOSITIONS FOR INHIBITION OF NLRP3 INFLAMMOSOME AND/OR LON PROTEASE
CN110169571A (zh) * 2019-05-28 2019-08-27 沈阳抗风竤生物技术有限公司 用于提高生育能力的食疗组合物
KR20220133807A (ko) * 2021-03-25 2022-10-05 주식회사 큐라클 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
JP5232658B2 (ja) * 2006-02-15 2013-07-10 エムディー バイオアルファ カンパニー リミテッド オキシドレダクターゼによるｎａｄ（ｐ）／ｎａｄ（ｐ）ｈ比を制御するための方法
EP2731971A1 (en) * 2011-07-12 2014-05-21 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
EA201600457A1 (ru) * 2013-12-12 2016-11-30 Альмираль, С.А. Фармацевтические композиции, содержащие диметилфумарат
CN105769594A (zh) * 2014-12-26 2016-07-20 罗继琴 一种治疗小面积白癜风的化妆品
TW201705961A (zh) * 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物

Also Published As

Publication number Publication date
US20190029987A1 (en) 2019-01-31
AU2017216861A1 (en) 2018-10-04
JP2019510743A (ja) 2019-04-18
WO2017137576A1 (en) 2017-08-17
EP3413884A1 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
NI202100014A (es) Metodos para reducir el riesgo de eventos cardiovasculares en un sujeto
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
CL2014000428A1 (es) Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.
GT201700143A (es) Derivado de biarilo como agonista de gpr120
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
AR091089A1 (es) Metodos de tratamiento que utilizan un compuesto de biguanida en una formulacion de liberacion demorada
BR112012032579A2 (pt) "terapia de diabetes"
AR088983A1 (es) Procedimiento para la preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
AR101740A1 (es) Terapia de combinación y composiciones
BR112018016300A2 (pt) fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenoso
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof
CL2015002346A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
CL2013000513A1 (es) Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante.
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
BR112014011223A2 (pt) método de tratar uma doença proliferativa
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes
CO2017005203A2 (es) Acido benzoico, derivados de acido benzoico y conjugados de acido carboxilico de heteroarilo de oximorfona, profarmacos, metodos de fabricacion y uso de los mismos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2556 DE 31/12/2019.

B350 Update of information on the portal [chapter 15.35 patent gazette]